Viridian Therapeutics VRDN
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$19.42M (9 inflow days, 11 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 40.5% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 16.79% to 15.04% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| FMR | Mutual Fund | 2026/Q3 | +904,397 | 15.4% |
| BlackRock | Mutual Fund | 2026/Q3 | +777,662 | 8.2% |
| Davern Capital Partners, LP | Hedge Fund | 2026/Q3 | +560,710 | 0.5% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +301,900 | 2.5% |
| Point72 Asset Management, L.P. | Hedge Fund | 2026/Q3 | +3,344,299 | 5.0% |
| Paradigm Biocapital Advisors LP | Hedge Fund | 2026/Q3 | +3,574,895 | 5.9% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +2,542,391 | 5.1% |
| Deep Track Capital, LP | VC/PE Fund | 2026/Q3 | +2,198,796 | 3.2% |
| Caligan Partners, LP | Hedge Fund | 2026/Q3 | +2,193,981 | 1.9% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +1,452,091 | 5.4% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +1,233,326 | 2.1% |
| FMR | Mutual Fund | 2026/Q3 | +1,225,363 | 14.7% |
| Fairmount Funds Management LLC | Hedge Fund | 2026/Q3 | +1,176,470 | 4.5% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +1,111,350 | 2.4% |
| Arrowstreet Capital, Limited Partnership | Mutual Fund | 2026/Q3 | +1,089,134 | 1.0% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 18 Aug 2026 | Jennifer Tousignant | Chief Legal Officer | Open Market Disposition | -4,212 | $24.50 | – |
| 18 Aug 2026 | Jennifer Tousignant | Chief Legal Officer | Derivative Exercise and Sale | -10,000 | $24.50 | – |
| 13 Aug 2026 | Radhika Tripuraneni | Chief Medical Officer | Derivative Exercise and Retained | +40,000 | $13.21 | 40,000 |
| 30 Jun 2026 | Arlene Morris | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 | 32,341 |
| 30 Jun 2026 | Jeffrey Ajer | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 | 32,341 |
| 30 Jun 2026 | Tomas Kiselak | Independent Chairperson of Board | Other Derivative Acquisition | +32,341 | $18.48 | 32,341 |
| 30 Jun 2026 | Christopher Cain | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 | 32,341 |
| 30 Jun 2026 | Jennifer Moses | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 | 32,341 |
| 30 Jun 2026 | Sarah Gheuens | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 | 32,341 |
| 10 May 2026 | Fairmount Funds Management LLC | Open Market Acquisition | +1,176,470 | $17.00 | 5,090,928 | |
| 3 Mar 2026 | Thomas Beetham | Chief Operating Officer | Intent to Sell (Form 144) | -3,048 | $30.19 | – |
| 3 Mar 2026 | Stephen Mahoney | Chief Executive Officer | Intent to Sell (Form 144) | -7,408 | $30.19 | – |
| 3 Mar 2026 | Seth Harmon | Chief Financial Officer | Intent to Sell (Form 144) | -2,031 | $30.19 | – |
| 3 Mar 2026 | Jennifer Tousignant | Chief Legal Officer | Intent to Sell (Form 144) | -1,675 | $30.19 | – |
| 2 Mar 2026 | Thomas Beetham | Chief Operating Officer | Sale to Issuer | -3,048 | $30.19 | 13,361 |
| 2 Mar 2026 | Thomas Beetham | Chief Operating Officer | Derivative Exercise and Retained | +9,409 | – | 13,361 |
| 2 Mar 2026 | Stephen Mahoney | Chief Executive Officer | Sale to Issuer | -7,408 | $30.19 | 33,349 |
| 2 Mar 2026 | Stephen Mahoney | Chief Executive Officer | Derivative Exercise and Retained | +18,357 | – | 33,349 |
| 2 Mar 2026 | Seth Harmon | Chief Financial Officer | Sale to Issuer | -2,031 | $30.19 | 7,850 |
| 2 Mar 2026 | Seth Harmon | Chief Financial Officer | Derivative Exercise and Retained | +6,267 | – | 7,850 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 17,042,236 | 15.0% | 9.1 |
| 15 Oct 2026 | 18,002,311 | 15.9% | 8.0 |
| 30 Sep 2026 | 17,965,668 | 15.9% | 8.9 |
| 15 Sep 2026 | 19,465,251 | 17.2% | 15.7 |
| 31 Aug 2026 | 19,511,841 | 17.2% | 16.6 |
| 14 Aug 2026 | 19,026,492 | 16.8% | 9.1 |
No comments yet — be the first to weigh in on VRDN.
Sign in to join the discussion.